Holen Sie sich die Stockscreener-App
14.36
1.02%
-0.16
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Janux Therapeutics VP Maria Dobek sells $28,878 in stock By Investing.com - Investing.com Australia
Janux Therapeutics VP Maria Dobek sells $28,878 in stock - Investing.com India
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics - Stock Titan
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target - TipRanks
Lifesci Capital Comments on JANX Q2 Earnings - MarketBeat
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics (JANX) Eps Diluted (TTM) - Zacks Investment Research
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $58 - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.41, Implies 178% Upside - TradingView
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating - marketscreener.com
Wedbush Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Piper Sandler Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $58 - Moomoo
Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating - Moomoo
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.94, Implies 182% Upside - TradingView
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14 - TipRanks
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
Janux Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BMS partnership boosts cash for Janux Therapeutics (NASDAQ: JANX) despite loss - Stock Titan
Janux Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipeline - Stock Titan
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M - marketscreener.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - Yahoo Finance
FMR LLC files 13G/A on JANX (NASDAQ: JANX) for 2.54M shares - Stock Titan
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):